Navigation Links
Hypercoagulable in Medical News

Portal vein thrombosis is common in extraportal vein obstruction

... related portal vein thrombosis patients are older and have grim prognoses. hypercoagulable state as a cause of portal vein thrombosis is less common. The idiopathic ... portal vein obstruction, in whom secondary cause is not known, should have hypercoagulable work up done to find out a treatable cause. Furthermore, as a primary ...

Retrospective Analysis Finds Treatment of Cancer Chemotherapy Patients With Epoetin Alfa Associated With Lower Drug Cost Than Darbepoetin Alfa

... in patients with a known history of a seizure disorder or underlying hematologic disease (e.g., sickle cell anemia, myelodysplastic syndromes, or hypercoagulable disorders). In some female patients, menses have resumed following PROCRIT therapy; the possibility of pregnancy should be discussed and the ...

Final Patient Completes Treatment In Boehringer Ingelheim's RE-LY(R) Study, The Largest Atrial Fibrillation Outcomes Trial To Date

... with the North American Society of Pacing and Electrophysiology. Circulation 2001;104:2118-2150 (2) Lip GHY. Does atrial fibrillation confer a hypercoagulable state? Lancet 1995;346:1313-4 (3) American Heart Association. "2008 Heart Disease and Stroke Statistics." (4) Hart RG, Pearce LA, Aguilar ...

Modeling Simulation Predicts Potential Negative Impact on U.S. Blood Supply if ESA Use Limited for Chemotherapy-Induced Anemia

... with a known history of a seizure disorder or underlying hematologic disease (e.g., sickle cell anemia, myelodysplastic syndromes, or hypercoagulable disorders). -- In some female patients, menses have resumed following PROCRIT therapy; the possibility of pregnancy should be discussed and ...

Updated Analysis of 2001 Epoetin Alfa Study Posted

... with a known history of a seizure disorder or underlying hematologic disease (e.g., sickle cell anemia, myelodysplastic syndromes, or hypercoagulable disorders). -- In some female patients, menses have resumed following PROCRIT therapy; the possibility of pregnancy should be discussed and the ...

Ortho Biotech to Submit Official Request for Reconsideration to CMS Regarding ESA Coverage Policy

... with a known history of a seizure disorder or underlying hematologic disease (e.g., sickle cell anemia, myelodysplastic syndromes, or hypercoagulable disorders). -- In some female patients, menses have resumed following PROCRIT therapy; the possibility of pregnancy should be discussed and the ...
Hypercoagulable in Medical Technology

Study Results of GAMMAGARD S/D and GAMMAGARD LIQUID in Patients with Mild-to-Moderate Alzheimer's Disease Announced

... age, impaired cardiac output, and/or known or suspected hyperviscosity, hypercoagulable disorders, and prolonged periods of immobilization. IGIV products can ... age, impaired cardiac output, and/or known or suspected hyperviscosity, hypercoagulable disorders, and prolonged periods of immobilization. Various minor ...

Baxter and The Alzheimer's Disease Cooperative Study Group to Pursue a Phase III Study of Gammagard Liquid in Patients With Alzheimer's Disease

... age, impaired cardiac output, and/or known or suspected hyperviscosity, hypercoagulable disorders, and prolonged periods of immobilization. IGIV products can ... age, impaired cardiac output, and/or known or suspected hyperviscosity, hypercoagulable disorders, and prolonged periods of immobilization. Various minor ...

Observational Study Finds Changes in Medicare Reimbursement for Erythropoiesis-Stimulating Agents Associated With Increased Need for Blood Transfusion

... in patients with a known history of a seizure disorder or underlying hematologic disease (e.g., sickle cell anemia, myelodysplastic syndromes, or hypercoagulable disorders). In some female patients, menses have resumed following PROCRIT therapy; the possibility of pregnancy should be discussed and the ...

Data From Investigational Use of PROCRIT(R) (Epoetin alfa) Presented at American Society of Nephrology Annual Meeting

... with a known history of a seizure disorder or underlying hematologic disease (e.g., sickle cell anemia, myelodysplastic syndromes, or hypercoagulable disorders). -- In some female patients, menses have resumed following PROCRIT therapy; the possibility of pregnancy should be discussed and ...

Baxter Initiates Phase III Trial for the Treatment of Alzheimer's Disease

... a history of atherosclerosis, multiple cardiovascular risk factors, advanced age, impaired cardiac output, and/or known or suspected hyperviscosity, hypercoagulable disorders, and prolonged periods of immobilization. IGIV products can contain blood group antibodies that may cause a positive direct antiglobulin ...

Observational Studies Assess the Potential Impact of Limiting Erythropoiesis-Stimulating Agent Availability on Frequency of Blood Transfusions

... patients with a known history of a seizure disorder or underlying hematologic disease (e.g., sickle cell anemia, myelodysplastic syndromes or hypercoagulable disorders). -- In some female patients, menses have resumed following PROCRIT therapy; the possibility of pregnancy should be discussed and the ...

New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting

... patients with a known history of a seizure disorder or underlying hematologic disease (e.g., sickle cell anemia, myelodysplastic syndromes or hypercoagulable disorders). -- In some female patients, menses have resumed following PROCRIT therapy; the possibility of pregnancy should be discussed and the ...

Data From Ortho Biotech-Sponsored Studies to be Presented at National Kidney Foundation 2008 Spring Clinical Meetings

... patients with a known history of a seizure disorder or underlying hematologic disease (e.g., sickle cell anemia, myelodysplastic syndromes or hypercoagulable disorders). -- In some female patients, menses have resumed following PROCRIT therapy; the possibility of pregnancy should be discussed and the ...

Baxter Presents Latest Clinical Trial Results of GAMMAGARD LIQUID Administered Subcutaneously

... a history of atherosclerosis, multiple cardiovascular risk factors, advanced age, impaired cardiac output, and/or known or suspected hyperviscosity, hypercoagulable disorders, and prolonged periods of immobilization. IGIV products can contain blood group antibodies that may cause a positive direct antiglobulin ...

Ortho Biotech Statement on U.S. Food and Drug Administration Oncologic Drugs Advisory Committee Vote

... patients with a known history of a seizure disorder or underlying hematologic disease (e.g., sickle cell anemia, myelodysplastic syndromes or hypercoagulable disorders). -- In some female patients, menses have resumed following PROCRIT therapy; the possibility of pregnancy should be discussed and the ...
Hypercoagulable in Medical Products

Sonoclot Coagulation & Platelet Function Analyzer

Description:... to manage anticoagulant therapy, assess platelet function, control blood product usage, differentiate mechanical versus hemostatic bleeders, identify hypercoagulable and heparin resistant patients, and screen for hyperfibrinolysis. Clinical areas include open heart surgery, liver transplant surgery, vascular ...
Company:Sienco, Inc.
Hypercoagulable in Medical Dictionary

Hypercoagulable states

... hypercoagulable states Definition: hypercoagulable states are conditions that may lead to the ... can develop in either arteries or veins. hypercoagulable States and Clotting Risk - Source:MedicineNet ...

Antithrombin III

... III , fibrinogen , ... antibodies in blood (anticardiolipin antibodies, lupus anticoagulant), cancer (though most patients with a hypercoagulable state do not have cancer ), elevated blood homocysteine levels, and inherited protein deficiencies ( antithrombin III , ... ...

Thrombophlebitis

... and discolouration of the leg Thrombophlebitis - pain , redness and swelling of the superficial veins. return to top ... There are numerous hypercoagulable states . Each has different causes and each increases a person's chances of developing blood clots such as those associated with thrombophlebitis ...
Hypercoagulable in Biological Technology

Baxter to Launch GARDian(TM), a Groundbreaking Initiative That Helps Provide Continued Access to GAMMAGARD for Current Patients

... output, and/or known or suspected hyperviscosity, hypercoagulable disorders, and prolonged periods of ... output, and/or known or suspected hyperviscosity, hypercoagulable disorders, and prolonged periods of ... output, and/or known or suspected hyperviscosity, hypercoagulable disorders, and prolonged periods of ...

Soliris(R) Reduced Measures of Thrombosis and Inflammation, and Decreased Indicators of Pulmonary Hypertension, in Studies of Patients with PNH

... showed that prior to treatment with Soliris, patients with PNH exhibited a hypercoagulable state as indicated by elevated levels of key inflammatory and ... of thrombosis and were also not previously transfused, exhibited a hypercoagulable state. In these patients, Soliris treatment was observed to result in a ...

Centocor Ortho Biotech Data to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting

... in patients with a known history of a seizure disorder or underlying hematologic disease (e.g., sickle cell anemia, myelodysplastic syndromes, or hypercoagulable disorders). In some female patients, menses have resumed following PROCRIT therapy; the possibility of pregnancy should be discussed and the ...

Phase III Trial Begins for GAMMAGARD LIQUID Plus rHuPH20 in Primary Immunodeficiency Patients

... a history of atherosclerosis, multiple cardiovascular risk factors, advanced age, impaired cardiac output, and/or known or suspected hyperviscosity, hypercoagulable disorders, and prolonged periods of immobilization. IGIV products can contain blood group antibodies that may cause a positive direct ...

Study Suggests GAMMAGARD LIQUID May Target the Primary Pathway Involved in Alzheimer's Disease

... a history of atherosclerosis, multiple cardiovascular risk factors, advanced age, impaired cardiac output, and/or known or suspected hyperviscosity, hypercoagulable disorders, and prolonged periods of immobilization. IGIV products can contain blood group antibodies that may cause a positive direct antiglobulin ...

Ortho Biotech Modifies Prescribing Information for PROCRIT(R) (Epoetin alfa)

... patients with a known history of a seizure disorder or underlying hematologic disease (e.g., sickle cell anemia, myelodysplastic syndromes or hypercoagulable disorders). -- In some female patients, menses have resumed following PROCRIT therapy; the possibility of pregnancy should be discussed and the ...

Ortho Biotech Statement On JAMA Publication Regarding Erythropoiesis-Stimulating Agents

... patients with a known history of a seizure disorder or underlying hematologic disease (e.g., sickle cell anemia, myelodysplastic syndromes or hypercoagulable disorders). -- In some female patients, menses have resumed following PROCRIT therapy; the possibility of pregnancy should be discussed and the ...

Ortho Biotech Modifies Prescribing Information for PROCRIT(R) (Epoetin alfa) Label Reflects Recommendations from Recent FDA Advisory Committee Meetings

... with a known history of a seizure disorder or underlying hematologic disease (e.g., sickle cell anemia, myelodysplastic syndromes, or hypercoagulable disorders). * In some female patients, menses have resumed following PROCRIT therapy; the possibility of pregnancy should be discussed and the ...

Ortho Biotech Supports FDA Advisory Committees' Recommendations on Use of ESAs in Chronic Renal Failure Patients

... patients with a known history of a seizure disorder or underlying hematologic disease (eg, sickle cell anemia, myelodysplastic syndromes, or hypercoagulable disorders). -- In some female patients, menses have resumed following PROCRIT therapy; the possibility of pregnancy should be discussed and the ...

Baxter and Halozyme Announce Collaboration for Development of Subcutaneous GAMMAGARD LIQUID(TM) Administration Using Enhanze(TM) Technology

... a history of atherosclerosis, multiple cardiovascular risk factors, advanced age, impaired cardiac output, and/or known or suspected hyperviscosity, hypercoagulable disorders, and prolonged periods of immobilization. IGIV products can contain blood group antibodies that may cause a positive direct antiglobulin ...
Other Contents
(Date:8/3/2015)... ... August 03, 2015 , ... A July 13 article from The ... Found to Release Natural Painkiller That Can Last 'For Five Weeks'" discusses the ... report, the new study showed that harvesting stem cell-rich bone marrow from the hip, ...
(Date:8/3/2015)... ... August 03, 2015 , ... Illinois Health & Science (IHS) has ... , The acquisition includes all of IBAM NA’s cyclotron sites and research and development ... robust regionally located business, as well as a large manufacturing hub in Noblesville, Indiana,” ...
(Date:8/3/2015)... Ramon, CA (PRWEB) , ... August 03, 2015 ... ... leading global insurance brokerage firm, announced today that Joe Williams has joined its ... development, sales, and delivering HUB's differentiated service model to his clients. Mr. Williams ...
(Date:8/3/2015)... Portland, Ore. (PRWEB) , ... August 03, 2015 ... ... President of Government Programs, with accountability for overall performance of the company’s Medicare ... a key focus of Cambia’s strategy to deliver better health for members. In ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... leading provider of medical information, risk management and investigative services, has introduced ... direction toward focused, expert information solutions that improve business outcomes for its ...
Breaking Medicine News(10 mins):Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 2Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 3Health News:Illinois Health & Science Expands Nuclear Medicine Footprint With Purchase of IBA Molecular North America, Inc. 2Health News:HUB International Insurance Services Announces Joe Williams Has Joined its Northern California Employee Benefits Division 2Health News:Cambia Health Solutions Names Scott Powers President of Government Programs 2Health News:EMSI Announces New Branding: Powerful Information. Improved Outcomes. 2
(Date:7/23/2015)... Inc. (NASDAQ: AWRE ), a leading supplier of biometrics ... quarter ended June 30, 2015.  Revenue for ... of 33% compared to $6.8 million in the same quarter ... was $0.3 million, or $0.01 per diluted share, which compared ... same period a year ago.  Lower revenue ...
(Date:7/21/2015)... , July 21, 2015 Today, ZTE announced ... received as well as expected revenues in 2015 that relate to ... communicated revenue guidance of approximately 2,200 MSEK for 2015. ... a leading smartphone manufacturer in China and ... 02 5 for Axon , ...
(Date:7/21/2015)... NEW YORK , July 21, 2015 /PRNewswire/ ... critical systems, as seen in the recent U.S. ... enterprises a solution to the infosec conundrum, but ... data is stored. To address this dilemma, Biometrics-as-a-Service ... of its Biometric Tokenization SDK for third party ...
Breaking Biology News(10 mins):Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6FPC's Touch Fingerprint Sensor FPC1025 in ZTE's Smartphone Axon 2HYPR Corp. Launches Industry First Biometric Tokenization Platform 2HYPR Corp. Launches Industry First Biometric Tokenization Platform 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 4
Other TagsOther Tags